Biogen Abandons Alzheimer Drug Aduhelm After Years of Tumult (1)

Biogen Inc. will stop studying and selling the controversial Alzheimer’s drug Aduhelm, capping years of debate over its efficacy and disappointment as it failed to meet commercial expectations.

Biogen is returning rights to the drug to Neurimmune, the private company that invented it, the pharmaceutical giant said in a statement. The Cambridge, Massachusetts-based drugmaker will redeploy resources to its other Alzheimer’s programs — including Leqembi, a medication it’s making with partner Eisai Co.

The move resolves a conundrum for Biogen Chief Executive Officer Chris Viehbacher over what to do about Aduhelm as the company focuses on ...